Tag
Sun Pharmaceutical Industries has agreed to acquire Organon & Co in an all-cash deal worth about $11.75 billion, including debt, at $14.00 per share. The deal gives Sun Pharma full ownership of Organon's women's health, biosimilars, and established medicines businesses. This is one of the largest foreign acquisitions
Sun Pharmaceutical Industries has announced a $11.75 billion acquisition of Organon & Co., a major US pharma firm with a presence in over 140 countries. The deal significantly expands Sun Pharma's women's health and biosimilars portfolio. Financing terms and regulatory clearances across multiple markets are the key
Sun Pharma has agreed to buy U.S. healthcare firm Organon in an $11.75 billion deal. Organon, a Merck spinoff from 2021, operates in women's health, biosimilars, and branded medicines. The deal would be Sun Pharma's biggest acquisition to date.
Sun Pharma has agreed to acquire Organon & Co. for $11.75 billion in an all-cash deal, one of India's largest pharma acquisitions. The merger pushes Sun Pharma into the global top 25 by revenue and establishes it as a top-10 biosimilar player. The deal is expected to close in early 2027, pending regulatory and
Sun Pharmaceutical Industries has agreed to acquire U.S.-based Organon & Co in an all-cash deal worth $11.75 billion. The deal would be one of the largest overseas acquisitions by an Indian pharma company and expands Sun Pharma's presence in women's health, biosimilars, and branded medicines.
Sun Pharma is set to acquire US drugmaker Organon for $12.5 billion, paying $4.5 billion in equity and assuming $8.5 billion in debt. The deal, Sun's largest ever, beats out a rival EQT-Gruenthal consortium bid. An official announcement is expected Sunday night or by Monday.
Tag
Sun Pharmaceutical Industries has agreed to acquire Organon & Co in an all-cash deal worth about $11.75 billion, including debt, at $14.00 per share. The deal gives Sun Pharma full ownership of Organon's women's health, biosimilars, and established medicines businesses. This is one of the largest foreign acquisitions
2mo ago · 1 min · Business
Sun Pharmaceutical Industries has announced a $11.75 billion acquisition of Organon & Co., a major US pharma firm with a presence in over 140 countries. The deal significantly expands Sun Pharma's women's health and biosimilars portfolio. Financing terms and regulatory clearances across multiple markets are the key
2mo ago · 1 min · Business
Sun Pharma has agreed to buy U.S. healthcare firm Organon in an $11.75 billion deal. Organon, a Merck spinoff from 2021, operates in women's health, biosimilars, and branded medicines. The deal would be Sun Pharma's biggest acquisition to date.
2mo ago · 1 min · Business
Sun Pharma has agreed to acquire Organon & Co. for $11.75 billion in an all-cash deal, one of India's largest pharma acquisitions. The merger pushes Sun Pharma into the global top 25 by revenue and establishes it as a top-10 biosimilar player. The deal is expected to close in early 2027, pending regulatory and
2mo ago · 1 min · Business
Sun Pharmaceutical Industries has agreed to acquire U.S.-based Organon & Co in an all-cash deal worth $11.75 billion. The deal would be one of the largest overseas acquisitions by an Indian pharma company and expands Sun Pharma's presence in women's health, biosimilars, and branded medicines.
2mo ago · 1 min · Business
Sun Pharma is set to acquire US drugmaker Organon for $12.5 billion, paying $4.5 billion in equity and assuming $8.5 billion in debt. The deal, Sun's largest ever, beats out a rival EQT-Gruenthal consortium bid. An official announcement is expected Sunday night or by Monday.
2mo ago · 1 min · Business
— End of feed —